

<b>Reference:</b>	FOI.17373.25
<b>Subject:</b>	Treatment of inflammatory diseases
<b>Date of Request:</b>	20 May 2025

**Request and response:**

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

**Appendix A**

1. How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jan 2025 to the end of Mar 2025?

*Please use the latest available 3 months if Jan to Mar is not available and specify which 3 months has been used.*

Hywel Dda University Health Board is unable to provide you with the exact number of cases due to the low number (less than 5). Where the figures in the tables overleaf have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients, as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

The UHB provides within the table below as requested, the number of Dermatology, Gastroenterology and Rheumatology patients, treated with the listed medications, for any disease, during the period 1 January to 31 March 2025.

<b>Drug Name</b>	<b>Dermatology</b>	<b>Gastroenterology</b>	<b>Rheumatology</b>
Adalimumab	83	144	294
Apremilast	8	0	26
Bimekizumab	0	0	57
Brodalumab	*	0	0
Certolizumab Pegol	*	0	0
Deucravacitinib	*	0	41
Etanercept	0	0	0

Guselkumab	*	0	187
Infliximab (Remicade)	0	0	0
Infliximab (Biosimilars)	0	10	*
Ixekizumab	0	0	30
Risankizumab	*	0	0
Secukinumab	*	98	14
Tildrakizumab	0	0	0
Ustekinumab	*	0	10
Upadacitinib	0	*	0
Vedolizumab	0	*	0
Filgotinib	31	57	*
Golimumab	0	0	25
Mirikizumab	0	0	7
Ozanimod	37	0	52
Etrasimod	*	0	0
Tofacitinib	0	0	91
Baricitinib	0	*	*
Rituximab	9	49	24
Sarilumab	22	114	10
Tocilizumab	0	122	*

2. How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Jan 2025 to the end of Mar 2025?  
*Please use the latest available 3 months if Jan to Mar is not available and specify which 3 months has been used.*

The UHB provides within the table below as requested, the number of Dermatology, Gastroenterology and Rheumatology patients, treated with the listed medications, for any disease, during the period 1 January to 31 March 2025.

<b>Drug Name</b>	<b>Dermatology</b>	<b>Gastroenterology</b>	<b>Rheumatology</b>
Ustekinumab (Stelara)	0	*	0
Ustekinumab (Pyzchiva)	*	0	0
Ustekinumab (Uzpruvo)	22	112	10
Ustekinumab (Wezenla)	0	0	0